Does Switching From Trimethoprim/Sulfamethoxazole to Atovaquone Result in Less Hyperkalemia? A Single‐Center Retrospective Analysis in Heart Transplant Patients
- 12 May 2025
- journal article
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (4) , e70043
Abstract
Background: Trimethoprim/sulfamethoxazole (TMP/SMX) is commonly used after orthotopic heart transplant (OHT) for opportunistic infection (OI) prophylaxis, but its contribution to hyperkalemia is uncertain. Whether switching to atovaquone (ATQ), which has a narrower antimicrobial spectrum, affects infection risk and improves hyperkalemia has not been investigated. This study evaluated whether transitioning from TMP/SMX to ATQ in the setting of post‐OHT hyperkalemia is beneficial in lowering risk of recurrent hyperkalemia while maintaining OI prophylaxis efficacy. Methods: A single‐center retrospective review of OHT patients (January 2011–April 2022) compared those maintained on TMP/SMX with those switched to ATQ due to side effects, specifically hyperkalemia. The primary endpoint was the resolution of hyperkalemia, and the secondary endpoint was the combined infection rate. Results: Among 321 OHT recipients, 76% were switched to ATQ. Patients switched to ATQ had higher rates of severe and recurrent hyperkalemia and experienced numerically higher overall infection rates compared to TMP/SMX patients (27% vs. 52%; p < 0.001). However, in a Poisson regression model adjusted for immortal time bias, the incidence rate ratio (IRR) for infections with ATQ versus TMP/SMX was 1.32 (95% CI: 0.93–1.86; p = 0.119). Multivariable analyses excluding chronic kidney disease patients confirmed TMP/SMX's association with lower hyperkalemia rates (initial/recurrent). Age and diabetes independently predicted initial hyperkalemia. Conclusions: Transitioning from TMP/SMX to ATQ did not decrease hyperkalemia rates and was associated with a numerically higher incidence of infections, though this difference was not statistically significant. Hyperkalemia is likely multifactorial and often unresolved by switching from TMP/SMX. imageKeywords
This publication has 14 references indexed in Scilit:
- The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipientsThe Journal of Heart and Lung Transplantation, 2022
- Potential Consequences of Essential Drug Shortages in Canada: Brain Abscess due toNocardia farcinicaAssociated with Dapsone Prophylaxis forPneumocystis jiroveciiPneumoniaCanadian Journal of Infectious Diseases and Medical Microbiology, 2013
- Fludrocortisone Therapy in Renal Transplant Recipients with Persistent HyperkalemiaCase Reports in Transplantation, 2012
- Successful Heart Transplantation After 13 Hours of Donor Heart Ischemia With the Use of HTK Solution: A Case ReportTransplantation Proceedings, 2005
- Decreased mineralocorticoid receptor expression in blood cells of kidney transplant recipients undergoing immunosuppressive treatment: cost efficient determination by quantitative PCRJournal of Clinical Pathology, 2003
- Trimethoprim-Sulfamethoxazole RevisitedArchives of internal medicine (1960), 2003
- ORGAN PRESERVATION SOLUTIONS IN HEART TRANSPLANTATION-PATTERNS OF USAGE AND RELATED SURVIVAL1Transplantation, 1997
- ORGAN PRESERVATIONAnnual Review of Medicine, 1995
- Nephron segment-specific inhibition of Na+/K+-ATPase activity by cyclosporin AKidney International, 1993
- A Controlled Study of Trimethoprim-Sulfamethoxazole Prophylaxis of Urinary Tract Infection in Renal Transplant RecipientsClinical Infectious Diseases, 1982